Binimetinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 444 publications
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Journal: Future oncology (London, England)
Published: March 31, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: March 30, 2026
A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 24, 2026
Crystal structure of binimetinib (Form A), C17H15BrF2N4O3, from synchrotron X-ray powder diffraction data and density functional theory.
Journal: Acta crystallographica. Section E, Crystallographic communications
Published: March 23, 2026
Repurposing Ilaprazole as a PP5 TPR Domain Binder with Modulatory Effects on MAPK Signaling.
Journal: ACS medicinal chemistry letters
Published: February 02, 2026
Remission of metastatic duodenal cancer after treatment with BRAF inhibitor
Journal: Ugeskrift for laeger
Published: January 30, 2026
Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study.
Journal: The oncologist
Published: January 20, 2026
Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis.
Journal: Journal of thoracic disease
Published: December 21, 2025
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer.
Journal: Investigational new drugs
Published: December 18, 2025
From empirical caution to precision resumption: model-informed management of a binimetinib overdose in a frail elderly patient.
Journal: European journal of clinical pharmacology
Published: December 15, 2025
Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 09, 2025
Last Updated: 06/30/2026